NASDAQ · Financial Statements

Anbio Biotechnology (NNNN) Financial Statements

$3.81 NASDAQ: NNNN Market Cap $167.23M

Anbio Biotechnology most recently reported annual revenue of $9.0M, net profit of $6.0M. Revenue grew at an average annual rate of 22.5% over the last 4 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Anbio Biotechnology: Revenue rose from $4.0M in 2021 to $9.0M in 2025, a change of +125.0% over 4 years; net profit was positive in all 5 reported years; operating margin moved from 55.5% to 66.7%, a shift of +11.2 percentage points; the most recent year shows net profit of $6.0M.

Income Statement — 5 Years (USD millions)

Metric20212022202320242025
Revenue$4.0M$24.0M$7.0M$8.0M$9.0M
Operating Expenses$2.0M$13.0M$5.0M$6.0M$3.0M
Operating Profit$2.0M$10.0M$2.0M$2.0M$6.0M
Operating Margin55.5%43.3%29.2%24.4%66.7%
Other Income$0$0$0$0$1.0M
Interest$0$0$0$0$0
Depreciation$0$0$0$0$0
Profit Before Tax$3.0M$10.0M$2.0M$2.0M$6.0M
Tax$0$0$0$0$0
Net Profit$3.0M$10.0M$2.0M$2.0M$6.0M
EPS$0.03$0.07$0.01$0.06$0.16
Dividend Payout0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 7 Quarters (USD millions)

MetricJun '23Dec '23Jun '24Dec '24Jun '25Sep '25Dec '25
Revenue$3.0M$4.0M$6.0M$3.0M$5.0M$2.0M$5.0M
Operating Expenses$2.0M$3.0M$2.0M$4.0M$1.0M$1.0M$2.0M
Operating Profit$2.0M$1.0M$4.0M$-2.0M$4.0M$1.0M$3.0M
Operating Margin46.5%14.8%61.5%-68.6%73.5%59.1%59.1%
Interest$0$0$0$0$0$0$0
Profit Before Tax$2.0M$1.0M$4.0M$-1.0M$4.0M$1.0M$3.0M
Tax$0$0$0$0$0$0$0
Net Profit$2.0M$1.0M$4.0M$-1.0M$4.0M$1.0M$3.0M
EPS$0.04$0.02$0.09$-0.03$0.09$0.03$0.07

Over the 5 years reported for Anbio Biotechnology, cash stood at $8.0M in the latest year, shareholders' equity was $0.

Balance Sheet — 5 Years (USD millions)

Metric20212022202320242025
Total Assets$5.0M$14.0M$16.0M$19.0M$30.0M
Current Assets$5.0M$14.0M$16.0M$19.0M$30.0M
Cash$4.0M$7.0M$10.0M$12.0M$8.0M
Inventory$0$0$0$0$0
Receivables$1.0M$0$2.0M$1.0M$4.0M
Fixed Assets$0$0$0$0$0
Capital Work in Progress$0$0$0$0$0
Investments$0$2.0M$0$0$4.0M
Other Assets$0$0$0$0$0
Total Liabilities$2.0M$1.0M$1.0M$2.0M$0
Current Liabilities$2.0M$1.0M$1.0M$2.0M$0
Borrowings$0$0$0$0$0
Other Liabilities$2.0M$1.0M$1.0M$2.0M$0
Equity$0$0$0$0$0
Reserves$3.0M$13.0M$15.0M$17.0M$30.0M

For Anbio Biotechnology, operating cash flow was positive in 4 of 5 reported years; free cash flow in the latest year was negative at $7.0M; free cash flow was positive in 4 of 5 years.

Cash Flow Statement — 5 Years (USD millions)

Metric20212022202320242025
Operating Cash Flow$4.0M$4.0M$1.0M$2.0M$-7.0M
Investing Cash Flow$0$-2.0M$2.0M$0$-4.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$4.0M$3.0M$3.0M$2.0M$-4.0M
Free Cash Flow$4.0M$4.0M$1.0M$2.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.33
EV / EBITDA41.49
FCF Yield0.00%
Quick Ratio344.31
Interest Coverage—
Return 1Y-77.97%
Return 3Y—
Return 5Y—

Anbio Biotechnology (NNNN) financials — frequently asked questions

What is Anbio Biotechnology's annual revenue?

Anbio Biotechnology (NNNN) reported annual revenue of $9.0M in its most recent fiscal year.

What is Anbio Biotechnology's net profit?

Anbio Biotechnology (NNNN) reported net profit of $6.0M in its most recent fiscal year.

What is NNNN EV/EBITDA?

Anbio Biotechnology's enterprise value to EBITDA (EV/EBITDA) ratio is 41.49.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
NNNN Overview NNNN Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.